Go to deals
Healthcare

Dispensys AG has been acquired by Sulzer Mixpac AG

The owner of Dispensys AG has sold the company to Sulzer Mixpac AG. Financial details of this transaction have not been disclosed.

Dispensys develops and produces dispensers and cartridges for every 2-component application in the dental market such as for impression materials, temporary crown and bridge materials, cements, bleaching products and others. The owner of Dispensys wanted to focus on the development of new products.

Sulzer Mixpac is the world’s leading manufacturer and supplier of metering, mixing and dispensing systems and disposable mixers for reactive multicomponent materials.

Oaklins' team in Switzerland acted as the exclusive financial advisor to the seller.

Parties

Talk to the deal team

Jens Rutten

Partner
Zurich, Switzerland
Oaklins Switzerland

Related deals

Leika Medical Equipments Ltd. has been acquired by Angus Capital
Private Equity | Healthcare

Leika Medical Equipments Ltd. has been acquired by Angus Capital

The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.

Learn more
Phen’X Technologies has sold a majority stake to Ciclad
Private Equity | Healthcare | Industrial Machinery & Components

Phen’X Technologies has sold a majority stake to Ciclad

The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.

Learn more
Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Healthcare | TMT

Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments

Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).

Learn more